The Economic Burden of Anemia in Heart Failure

Heart Failure Clinics

Volumn 6, Issue 3, 2010, Pages 373-383

  Spence, Richard K ^a,b  

^a HAEMONETICS CORPORATION   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Anemia; Economic; Heart failure; Quality of life

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; ERYTHROPOIETIN; FRESH FROZEN PLASMA; HEMOGLOBIN; HEPCIDIN; IRON; METOPROLOL; NITRIC OXIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN; RENIN;

ACUTE HEART INFARCTION; ANEMIA; CARDIAC PATIENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG COST; DRUG DOSE INCREASE; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; HEALTH CARE COST; HEART FAILURE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION COST; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; LENGTH OF STAY; PLASMA TRANSFUSION; PNEUMONIA; POSTOPERATIVE INFECTION; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ANEMIA, IRON-DEFICIENCY; COMORBIDITY; COST-BENEFIT ANALYSIS; ERYTHROPOIETIN; HEALTH CARE COSTS; HEART FAILURE; HUMANS; PREVALENCE; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 77953618208     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2010.02.003     Document Type: Review

References (101)

1. Mitchell J.E. Emerging role of anemia in heart failure. Am J Cardiol 99 (2007) 15D-20D
2. Gonzalez-Juanatey J.R., Alegria Ezquerra E., Bertomeu Martinez V., et al. [Heart failure in outpatients: comorbidities and management by different specialists. The EPISERVE Study]. Rev Esp Cardiol 61 (2008) 611-619 [in Spanish]
3. Nanas J.N., Matsouka C., Karageorgopoulos D., et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48 (2006) 2485-2489
4. Grau-Amoros J., Formiga F., Jordana-Comajuncosa R., et al. [Anemia prevalence in heart failure. GESAIC study results]. Rev Clin Esp 208 (2008) 211-215 [in Spanish]
5. Stewart S., Wilkinson D., Hansen C., et al. Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation 118 (2008) 2360-2367
6. Newton J.D., and Squire I.B. Glucose and haemoglobin in the assessment of prognosis after first hospitalisation for heart failure. Heart 92 (2006) 1441-1446
7. Komajda M., Anker S.D., Charlesworth A., et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 27 (2006) 1440-1446
8. Choy C.K., Spencer A.P., and Nappi J.M. Prevalence of anemia in clinic patients with heart failure and cost analysis of epoetin treatment. Pharmacotherapy 27 (2007) 707-714
9. Egelykke K., Petersen H., and Haghfelt T.H. [Prevalence and significance of anaemia in patients with chronic congestive heart failure]. Ugeskr Laeger 168 (2006) 1860-1864 [in Danish]
10. Berry C., Norrie J., Hogg K., et al. The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J 151 (2006) 1313-1321
11. Dunlay S.M., Weston S.A., Redfield M.M., et al. Anemia and heart failure: a community study. Am J Med 121 (2008) 726-732
12. Fabbri G., Gorini M., Maggioni A.P., et al. [Italian Network on Congestive Heart Failure: ten-year experience]. G Ital Cardiol (Rome) 7 (2006) 689-694 [in Italian]
13. Dominguez Franco A., Pena Hernandez J., Perez Caravante M., et al. [Long-term prognosis value of anemia in a non-selected population with heart failure]. Med Clin (Barc) 128 (2007) 370-371 [in Spanish]
14. Tang W.H., Tong W., Jain A., et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 51 (2008) 569-576
15. Young J.B., Abraham W.T., Albert N.M., et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol 101 (2008) 223-230
16. Kazory A., and Ross E.A. Anemia: the point of convergence or divergence for kidney disease and heart failure?. J Am Coll Cardiol 53 (2009) 639-647
17. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 149 (2005) 391-401
18. Silverberg D.S., Wexler D., Iaina A., et al. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 26 (2006) 296-306
19. Anand I.S. Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med 6 Suppl 3 (2005) S13-S21
20. McCullough P.A., and Lepor N.E. The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. Rev Cardiovasc Med 6 (2005) 1-10
21. Cohen R.S., Mubashir A., Wajahat R., et al. The cardio-renal-anemia syndrome in elderly subjects with heart failure and a normal ejection fraction: a comparison with heart failure and low ejection fraction. Congest Heart Fail 12 (2006) 186-191
22. van der Putten K., Braam B., Jie K.E., et al. Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 4 (2008) 47-57
23. Iaina A., Silverberg D.S., Wexler D., et al. The cardio-renal anemia syndrome. Med Pregl 60 Suppl 2 (2007) 145-150
24. Sarmento P.M., Fonseca C., Marques F., et al. Acutely decompensated heart failure: characteristics of hospitalized patients and opportunities to improve their care. Rev Port Cardiol 25 (2006) 13-27
25. Maurer M.S., Burkhoff D., Fried L.P., et al. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. J Am Coll Cardiol 49 (2007) 972-981
26. Tarmonova L., Shutov A.M., and Chernysheva E.V. [Factors influencing left ventricular diastolic function in elderly patients with chronic heart failure]. Klin Med (Mosk) 85 (2007) 26-29 [in Russian]
27. Candia A.M., Villacorta Jr. H., and Mesquita E.T. Immune-inflammatory activation in heart failure. Arq Bras Cardiol 89 (2007) 183-190 201-8
28. Yndestad A., Damas J.K., Oie E., et al. Systemic inflammation in heart failure-the whys and wherefores. Heart Fail Rev 11 (2006) 83-92
29. Vasu S., Kelly P., and Lawson W.E. Anemia in heart failure-a concise review. Clin Cardiol 28 (2005) 454-458
30. Ferrucci L., Guralnik J.M., Woodman R.C., et al. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 118 (2005) 1288
31. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 16 Suppl 7 (2001) 36-40
32. Macdougall I.C., and Cooper A.C. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17 Suppl 11 (2002) 39-43
33. Means Jr. R.T. Recent developments in the anemia of chronic disease. Curr Hematol Rep 2 (2003) 116-121
34. Casadevall N. Cellular mechanism of resistance to erythropoietin. Nephrol Dial Transplant 10 Suppl 6 (1995) 27-30
35. Eisenstaedt R., Penninx B.W., and Woodman R.C. Anemia in the elderly: current understanding and emerging concepts. Blood Rev 20 (2006) 213-226
36. Matsumura I., and Kanakura Y. [Pathogenesis of anemia of chronic disease]. Nippon Rinsho 66 (2008) 535-539 [in Japanese]
37. Opasich C., Cazzola M., Scelsi L., et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26 (2005) 2232-2237
38. Kes P., Basic-Jukic N., Juric I., et al. [The cardiorenal syndrome and erythropoietin]. Acta Med Croatica 62 Suppl 1 (2008) 21-31 [in Croatian]
39. Jie K.E., Verhaar M.C., Cramer M.J., et al. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 291 (2006) F932-F944
40. Perunicic-Pekovic G., Pljesa S., Rasic Z., et al. Relationship between inflammatory cytokines and cardiorenal anemia syndrome: treatment with recombinant human erythropoietin (rhepo). Hippokratia 12 (2008) 153-156
41. Azizi M., Junot C., Ezan E., et al. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline. Clin Exp Pharmacol Physiol 28 (2001) 1066-1069
42. van der Meer P., Lipsic E., Westenbrink B.D., et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112 (2005) 1743-1747
43. Terrovitis J.V., Anastasiou-Nana M.I., Alexopoulos G.P., et al. Prevalence and prognostic significance of anemia in patients with congestive heart failure treated with standard vs high doses of enalapril. J Heart Lung Transplant 25 (2006) 333-338
44. van der Meer P., and van Veldhuisen D.J. [New applications of erythropoietin in cardiovascular disease: from haematopoiesis to cardiac protection]. Ned Tijdschr Geneeskd 152 (2008) 923-927 [in Dutch]
45. Usmanov R.I., Zueva E.B., Silverberg D.S., et al. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 21 (2008) 236-242
46. Adlbrecht C., Kommata S., Hulsmann M., et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 29 (2008) 2343-2350
47. Toblli J.E., Lombrana A., Duarte P., et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50 (2007) 1657-1665
48. Witte K.K., Desilva R., Chattopadhyay S., et al. Are hematinic deficiencies the cause of anemia in chronic heart failure?. Am Heart J 147 (2004) 924-930
49. Samuels-Reid J.H. Common problems in sickle cell disease. Am Fam Physician 49 (1994) 1477-1480 83-6
50. Gacon P.H., and Donatien Y. [Cardiac manifestations of sickle cell anemia]. Presse Med 30 (2001) 841-845 [in French]
51. Barnett C.F., Hsue P.Y., and Machado R.F. Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection. JAMA 299 (2008) 324-331
52. Fucharoen S., Ketvichit P., Pootrakul P., et al. Clinical manifestation of beta-thalassemia/hemoglobin E disease. J Pediatr Hematol Oncol 22 (2000) 552-557
53. Aessopos A., Kati M., and Tsironi M. Congestive heart failure and treatment in thalassemia major. Hemoglobin 32 (2008) 63-73
54. Mak G., Murphy N.F., and McDonald K. Anemia in heart failure: to treat or not to treat?. Curr Treat Options Cardiovasc Med 10 (2008) 455-464
55. Bayliss J., Norell M., Canepa-Anson R., et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 57 (1987) 17-22
56. Demers C., Mody A., Teo K.K., et al. ACE inhibitors in heart failure: what more do we need to know?. Am J Cardiovasc Drugs 5 (2005) 351-359
57. Cleland J.G., McGowan J., Clark A., et al. The evidence for beta blockers in heart failure. BMJ 318 (1999) 824-825
58. Palazzuoli A., Silverberg D., Iovine F., et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152 1096 (2006) e9-e15
59. Palazzuoli A., Silverberg D.S., Iovine F., et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 154 645 (2007) e9-e15
60. Parissis J.T., Kourea K., Panou F., et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 155 751 (2008) e1-7
61. Kourea K., Parissis J.T., Farmakis D., et al. Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerosis 199 (2008) 215-221
62. Kourea K., Parissis J.T., Farmakis D., et al. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 15 (2008) 365-369
63. Okonko D.O., Grzeslo A., Witkowski T., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 51 (2008) 103-112
64. Howlett J.G. Recognition and treatment of anemia in the setting of heart failure due to systolic left ventricular dysfunction. Expert Rev Cardiovasc Ther 6 (2008) 199-208
65. Garty M., Shotan A., Gottlieb S., et al. The management, early and one year outcome in hospitalized patients with heart failure: a national Heart Failure Survey in Israel-HFSIS 2003. Isr Med Assoc J 9 (2007) 227-233
66. Silverberg D.S., Wexler D., Blum M., et al. Effect of correction of anemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians. Isr Med Assoc J 5 (2003) 337-339
67. Iaina A., Silverberg D.S., and Wexler D. Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome. Nat Clin Pract Cardiovasc Med 2 (2005) 95-100
68. Anand I.S. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 52 (2008) 501-511
69. Szczech L.A., Barnhart H.X., Inrig J.K., et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74 (2008) 791-798
70. Silverberg D.S., Wexler D., Iaina A., et al. The role of correction of anaemia in patients with congestive heart failure: a short review. Eur J Heart Fail 10 (2008) 819-823
71. Ceresa M., Capomolla S., Pinna G., et al. Anemia in chronic heart failure patients: comparison between invasive and non-invasive prognostic markers. Monaldi Arch Chest Dis 64 (2005) 124-133
72. Tehrani F., Phan A., Morrissey R., et al. The prognostic value of anemia in patients with diastolic heart failure. Tex Heart Inst J 36 (2009) 220-225
73. Karaye K.M., and Sani M.U. Factors associated with poor prognosis among patients admitted with heart failure in a Nigerian tertiary medical centre: a cross-sectional study. BMC Cardiovasc Disord 8 (2008) 16
74. Latado A.L., Passos L.C., Darze E.S., et al. Comparison of the effect of anemia on in-hospital mortality in patients with versus without preserved left ventricular ejection fraction. Am J Cardiol 98 (2006) 1631-1634
75. O'Meara E., Clayton T., McEntegart M.B., et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation 113 (2006) 986-994
76. Felker G.M., Shaw L.K., Stough W.G., et al. Anemia in patients with heart failure and preserved systolic function. Am Heart J 151 (2006) 457-462
77. Sharma R., Francis D.P., Pitt B., et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 25 (2004) 1021-1028
78. Varadarajan P., Gandhi S., Sharma S., et al. Prognostic significance of hemoglobin level in patients with congestive heart failure and normal ejection fraction. Clin Cardiol 29 (2006) 444-449
79. Anand I., McMurray J.J., Whitmore J., et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 110 (2004) 149-154
80. O'Riordan E., and Foley R.N. Effects of anaemia on cardiovascular status. Nephrol Dial Transplant 15 Suppl 3 (2000) 19-22
81. Clark S.F. Iron deficiency anemia. Nutr Clin Pract 23 (2008) 128-141
82. Mozaffarian D., Nye R., and Levy W.C. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 41 (2003) 1933-1939
83. Szachniewicz J., Petruk-Kowalczyk J., Majda J., et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol 90 (2003) 303-308
84. Bansal N., Tighiouart H., Weiner D., et al. Anemia as a risk factor for kidney function decline in individuals with heart failure. Am J Cardiol 99 (2007) 1137-1142
85. Groenveld H.F., Januzzi J.L., Damman K., et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52 (2008) 818-827
86. Kosiborod M., Curtis J.P., Wang Y., et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med 165 (2005) 2237-2244
87. Allen L.A., Anstrom K., Horton J., et al. Relationship between anemia and health care costs in heart failure. J Card Fail 15 (2009) 639-726
88. Solid C.A., Foley R.N., Gilbertson D.T., et al. Anemia and cost in Medicare patients with congestive heart failure. Congest Heart Fail 12 (2006) 302-306
89. Nissenson A.R., Wade S., Goodnough T., et al. Economic burden of anemia in an insured population. J Manag Care Pharm 11 (2005) 565-574
90. Nordyke R.J., Kim J.J., Goldberg G.A., et al. Impact of anemia on hospitalization time, charges, and mortality in patients with heart failure. Value Health 7 (2004) 464-471
91. Ershler W.B., Chen K., Reyes E.B., et al. Economic burden of patients with anemia in selected diseases. Value Health 8 (2005) 629-638
92. Man-Fai Sim V., Nam M.C., Riley S., et al. Anaemia in older people with chronic heart failure: the potential cost. Technol Health Care 17 (2009) 377-385
93. The association of persistently low hemoglobin levels with medical expenditures in dialysis patients. Available at: (2006). http://www.cdrg.org/pub_pres/files/2006/15R_asn_06_low_hgb_costs.pdf Accessed January 4, 2010
94. Spence R.K. Medical and economic impact of anemia in hospitalized patients. Am J Health Syst Pharm 64 (2007) S3-10
95. Ferraris V.A., and Ferraris S.P. Risk factors for postoperative morbidity. J Thorac Cardiovasc Surg 111 (1996) 731-738 [discussion: 8-41]
96. Charlson M., Pompei P., Ales K., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
97. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 (2001) 1775-1780
98. Mancini D.M., and Kunavarapu C. Effect of erythropoietin on exercise capacity in anemic patients with advanced heart failure. Kidney Int Suppl (2003) S48-S52
99. Cleland J.G., Sullivan J.T., Ball S., et al. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol 46 (2005) 155-161
100. van Veldhuisen D.J., Dickstein K., Cohen-Solal A., et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 28 (2007) 2208-2216
101. Ghali J.K., Anand I.S., Abraham W.T., et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117 (2008) 526-535